Background: This study was done to determine antibodies to measles, mumps, and rubella within the first 2 weeks of life and 3 months of age in premature infants.

Methods: All premature infants (< 32 weeks' gestation) weighing less than 1,000 g and admitted to the neonatal intensive care unit were eligible for inclusion in the study. Measles, mumps, and rubella titers were obtained from the mother and from the infant during the first 2 weeks of life and at 3 months of age.

Results: A total of 44 maternal-infant pairs were enrolled. At birth, 45% of the infants were seronegative for measles, 55% for mumps, and 48% for rubella. Maternal samples revealed seronegativity in 14%, 3%, and 17%, respectively. By 3 months of age, 100% of infants were seronegative for mumps and rubella, and 94% were seronegative for measles.

Conclusions: The majority of prematurely born infants are seronegative for measles, mumps, and rubella by 3 months of age and therefore are presumably susceptible to infection during the first year of life.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00007611-199802000-00008DOI Listing

Publication Analysis

Top Keywords

mumps rubella
20
measles mumps
16
months age
12
infants seronegative
12
premature infants
8
weighing 1000
8
weeks life
8
life months
8
seronegative measles
8
rubella
6

Similar Publications

Background and objective Viral infections caused by cytomegalovirus, lymphocytic choriomeningitis virus, varicella-zoster virus, herpes simplex type 1 and type 2, rubella, measles, rubeola, HIV, West Nile virus, Lassa virus, and mumps are known to be associated with hearing loss. There have been reports of inner ear involvement in coronavirus disease 2019 (COVID-19) patients but the extent and variations in cochlear involvement of symptomatic and asymptomatic patients has not been adequately described. This study aimed to evaluate the hearing status among symptomatic and asymptomatic COVID-19 patients to address the prospects for routine screening for hearing loss in COVID-19 patients.

View Article and Find Full Text PDF

[Retrospective analysis in children with vaccination granuloma].

Dermatologie (Heidelb)

February 2025

Department of Dermatology and Allergy, Klinikum rechts der Isar, Technical University, München, Deutschland.

Background: Vaccine granulomas are a common (0.3-1%) adverse event (AE) of (accidentally) subcutaneously administered vaccines and specific immunotherapies containing aluminum conjugates. The clinical symptoms with persistent itching subcutaneous nodules, predominantly affect infants and young children on the lateral thigh.

View Article and Find Full Text PDF

The AEP 2025 Vaccination and Immunization Schedule recommended for children, adolescents and pregnant women residing in Spain features the following novelties: Due to the increase in measles cases and outbreaks in recent years, we recommend advancing the second dose of measles, mumps and rubella (MMR) vaccine to 2 years of age. As a consequence of the above, since many autonomous communities (ACs) use the quadrivalent vaccine for the second dose of MMR and varicella vaccines, we recommend, for all ACs, advancing the second dose of varicella vaccine to 2 years of age. Due to the very significant increase in cases of pertussis since late 2023 and especially in 2024, we recommend advancing the dose of Tdap given in adolescence to 10-12 years of age.

View Article and Find Full Text PDF

Anogenital warts (AGW) including multiple types of human papillomavirus (HPV) are prevalent. In this context, oncogenic HPV infection leads to anogenital cancers and the lesion is more persistent. Several research on AGW therapy with measles, mumps, and rubella (MMR) vaccine injections have been successful without adverse effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!